GSK's ViiV Healthcare Says HIV Treatment Cabenuva's Latest Trial Meets Primary Endpoint
MT newswire2026/10/06 13:4209:42 AM EDT, 10/06/2026 (MT Newswires) -- ViiV Healthcare, which is majority owned by GSK (GSK), said Tuesday that a phase 3b study has met its primary endpoint, showing that at six months, Cabenuva saw "superior rates of viral suppression" compared with oral antiretroviral therapy in adults and adolescents with HIV-1, who had detectable virus when they started the trial. The trial has enrolled 326 participants in eight countries at 85 study sites, the company said. The results follow a previous trial that showed that Cabenuva was superior to daily oral therapy in keeping viral suppression for people with HIV who had reached viral suppression on oral antiretroviral therapy but had a history of adherence challenges, ViiV said. The latest trial addressed a "remaining evidence gap by evaluating direct initiation of the regimen in people who still had detectable virus at study entry," the company said. ViiV said the latest results will now be shared with health regulators. Price: 46.77, Change: +0.24, Percent Change: +0.52
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
The new Roadster is about to debut: Is "Tesla can fly" just hype or reality?
BUZZ - Super Micro appoints Mark Long as Chief Financial Officer; shares fall
The US stock market opened mixed, with the Nasdaq down 331 points.
"Super bull" Yardeni lowers S&P year-end target: Earnings are not the problem, valuation is
Yardeni Research has lowered its year-end S&P 500 target to 7,900 points and reduced its valuation target to 18.6 times, mainly due to risk-off sentiment suppressing valuations rather than deteriorating earnings. Despite facing risk aversion and policy risks, Yardeni remains optimistic about corporate earnings and the medium-to-long-term economy, viewing pullbacks as buying opportunities.
Crypto prices
More
